{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:29:58Z","timestamp":1788838198300,"version":"build-2803163510"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Providing the most efficacious frontline treatment for newly diagnosed multiple myeloma (NDMM) is critical for patient outcomes. No direct comparisons have been made between bortezomib + lenalidomide + dexamethasone (VRD) and bortezomib + thalidomide + dexamethasone (VTD) induction regimens in transplant-eligible NDMM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>An integrated analysis was performed using patient data from four trials meeting prespecified eligibility criteria: two using VRD (PETHEMA GEM2012 and IFM 2009) and two using VTD (PETHEMA GEM2005 and IFM 2013-04).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The primary endpoint was met, with VRD demonstrating a noninferior rate of at least very good partial response (\u2265 VGPR) after induction <jats:italic>vs<\/jats:italic> VTD. GEM comparison demonstrated improvement in the \u2265 VGPR rate after induction for VRD <jats:italic>vs<\/jats:italic> VTD (66.3% <jats:italic>vs<\/jats:italic> 51.2%; <jats:italic>P<\/jats:italic> = .00281) that increased after transplant (74.4% <jats:italic>vs<\/jats:italic> 53.5%). Undetectable minimal residual disease rates post induction (46.7% <jats:italic>vs<\/jats:italic> 34.9%) and post transplant (62.4% <jats:italic>vs<\/jats:italic> 47.3%) support the benefit of VRD <jats:italic>vs<\/jats:italic> VTD. Treatment-emergent adverse events leading to study and\/or treatment discontinuation were less frequent with VRD (3%, GEM2012; 6%, IFM 2009) <jats:italic>vs<\/jats:italic> VTD (11%, IFM 2013-04).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These results supported the benefit of VRD over VTD for induction in transplant-eligible patients with NDMM. The trials included are registered with <jats:uri>ClinicalTrials.gov<\/jats:uri> (NCT01916252, NCT01191060, NCT00461747, and NCT01971658).<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.1197340","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T12:44:22Z","timestamp":1698929062000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma"],"prefix":"10.3389","volume":"13","author":[{"given":"Laura","family":"Rosi\u00f1ol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Hebraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Oriol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laur\u00e8ne","family":"Colin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"R\u00edos Tamayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Hulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jes\u00fas","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Caillot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Teodoro","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Arnulf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Macro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"San-Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Belhadj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"Lahuerta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Brigid","family":"Garelik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Blad\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"995","DOI":"10.3324\/haematol.2016.148882","article-title":"Treatment of relapsed and refractory multiple myeloma","volume":"101","author":"Sonneveld","year":"2016","journal-title":"Haematologica"},{"key":"B3","unstructured":"Surveillance Epidemiology and End Results (SEER): National Cancer Institute2014"},{"key":"B4","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"5","author":"Dimopoulos","year":"2021","journal-title":"Hemasphere"},{"key":"B5","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3324\/haematol.2017.174573","article-title":"From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives","volume":"103","author":"Gay","year":"2018","journal-title":"Haematologica"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline","volume":"37","author":"Mikhael","year":"2019","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12685","article-title":"Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population","volume":"164","author":"Liwing","year":"2014","journal-title":"Br J Haematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0147381","article-title":"Real-world use of 3rd line therapy for multiple myeloma in Austria: an Austrian Myeloma Registry (AMR) analysis of the therapeutic landscape and clinical outcomes prior to the use of next generation myeloma therapeutics","volume":"11","author":"Willenbacher","year":"2016","journal-title":"PloS One"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14213","article-title":"Multiple myeloma: patient outcomes in real-world practice","volume":"175","author":"Yong","year":"2016","journal-title":"Br J Haematol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/bjh.14193","article-title":"Multiple myeloma: practice patterns across Europe","volume":"175","author":"Raab","year":"2016","journal-title":"Br J Haematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.4065\/79.7.867","article-title":"Clinical course of patients with relapsed multiple myeloma","volume":"79","author":"Kumar","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.1060","article-title":"Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 trials","volume":"27","author":"Harousseau","year":"2009","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11534","article-title":"Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma","volume":"92","author":"van de Velde","year":"2007","journal-title":"Haematologica"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704313","article-title":"High-dose therapy\/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission","volume":"33","author":"Nadal","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.220","article-title":"Association of response endpoints with survival outcomes in multiple myeloma","volume":"28","author":"Lonial","year":"2014","journal-title":"Leukemia"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-693580","article-title":"VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial","volume":"127","author":"Moreau","year":"2016","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2016.1196127","article-title":"Are maintenance and continuous therapies indicated for every patient with multiple myeloma","volume":"9","author":"Musto","year":"2016","journal-title":"Expert Rev Hematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-408922","article-title":"Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA\/GEM study","volume":"120","author":"Rosinol","year":"2012","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(10)61424-9","article-title":"Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as Induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised Phase 3 study","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.7618","article-title":"Community-based phase IIIB trial of three UPFRONT bortezomib-based myeloma regimens","volume":"33","author":"Niesvizky","year":"2015","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/927105","article-title":"Subcutaneous administration of bortezomib in combination with thalidomide and dexamethasone for treatment of newly diagnosed multiple myeloma patients","volume":"2015","author":"Wu","year":"2015","journal-title":"BioMed Res Int"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.124347","article-title":"Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial","volume":"100","author":"Merz","year":"2015","journal-title":"Haematologica"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000241","article-title":"Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma","volume":"134","author":"Rosinol","year":"2019","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41408-020-0311-8","article-title":"Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)","volume":"10","author":"Durie","year":"2020","journal-title":"Blood Cancer J"},{"key":"B27","first-page":"8521","article-title":"Bortezomib, lenalidomide, and dexamethasone (VRD) is superior to lenalidomide, adriamycin, and dexamethasone (RAD) prior to risk-adapted transplant in newly diagnosed myeloma","volume-title":"J Clin Oncol","author":"Knop","year":"2020"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00263-0","article-title":"Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"Lancet Haematol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","article-title":"Tutorial in biostatistics: propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group","volume":"17","author":"D\u2019Agostino","year":"1998","journal-title":"Statist Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.112037","article-title":"Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma","volume":"100","author":"Dimopoulos","year":"2015","journal-title":"Haematologica"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1984.10478078","article-title":"Reducing bias in observational studies using subclassification on the propensity score","volume":"79","author":"Rosenbaum","year":"1984","journal-title":"J Am Stat Assoc"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"key":"B34","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2004.00382.x","article-title":"Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma","volume":"74","author":"Tosi","year":"2005","journal-title":"Eur J Haematol"},{"key":"B36","volume-title":"Thalidomide. [Summary of Product Characteristics]","year":"2018"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00860","article-title":"Minimal residual disease in multiple myeloma: current landscape and future applications with immunotherapeutic approaches","volume":"10","author":"Kostopoulos","year":"2020","journal-title":"Front Oncol"},{"key":"B38","volume-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines","year":"2023"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/EDBK_280221","article-title":"Newly diagnosed myeloma in 2020","volume":"40","author":"Moreau","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147323","article-title":"Elotuzumab in combination with lenalidomide, bortezomib, dexamethasone and autologous transplantation for newly-diagnosed multiple myeloma: results from the randomized phase III GMMG-HD6 trial","volume":"138","author":"Goldschmidt","year":"2021","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.247130","article-title":"Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial","volume":"106","author":"Jackson","year":"2021","journal-title":"Haematologica"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-118868","article-title":"Maximizing pre-transplant response is associated with improved outcome for myeloma patients: exploratory analysis of the Myeloma XI trial","volume":"132","author":"Pawlyn","year":"2018","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01045","article-title":"Consolidation and maintenance in newly diagnosed multiple myeloma","volume":"39","author":"Sonneveld","year":"2021","journal-title":"J Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.00685","article-title":"Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 trial","volume":"37","author":"Stadtmauer","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1197340\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T12:44:26Z","timestamp":1698929066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1197340\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,2]]},"references-count":44,"alternative-id":["10.3389\/fonc.2023.1197340"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1197340","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,2]]},"article-number":"1197340"}}